

CITATION REPORT

List of articles citing

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

DOI: 10.1016/s0140-6736(15)00803-x
Lancet, The, 2016, 387, 679-690.

Source: <https://exaly.com/paper-pdf/65703311/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1183	The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. 2016 , 49, 139-48		44
1182	Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis?. 2016 , 67, 286		
1181	Liraglutide's use in treatment of non-alcoholic fatty liver: an evaluation of the non-alcoholic steatohepatitis study. 2016 , 5, 515-518		2
1180	A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. 2016 , 2016, 7109270		42
1179	Randomized, Double-Blinded, Double-Dummy, Active-Controlled, and Multiple-Dose Clinical Study Comparing the Efficacy and Safety of Mulberry Twig (<i>Ramulus Mori</i> , Sangzhi) Alkaloid Tablet and Acarbose in Individuals with Type 2 Diabetes Mellitus. 2016 , 2016, 7121356		7
1178	Rationale and Design of RNAFH Study: Effect of Rosuvastatin (10 mg/d) on Nonalcoholic Fatty Liver in Metabolic Syndrome Patients without Overt Diabetes Evaluated by H-Magnetic Resonance Spectroscopy. 2016 , 2016, 8454751		0
1177	A Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease. 2016 , 2016, 6491420		8
1176	Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. 2016 , 14, 494-497		11
1175	The Flexibility of Ectopic Lipids. 2016 , 17,		21
1174	Pathophysiology of Non Alcoholic Fatty Liver Disease. 2016 , 17,		88
1173	Autophagy in Non-Alcoholic Fatty Liver Disease (NAFLD). 2016 ,		1
1172	Identifying patients with nonalcoholic steatohepatitis that are nonresponders to therapy. 2016 , 64, 2265-2266		4
1171	Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. 2016 , 18, 882-91		105
1170	Liraglutide for patients with non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2016 , 387, 2378-9	40	3
1169	Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease. 2016 , 17, 1273-1288		10
1168	Reply. 2016 , 64, 2266-2267		
1167	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. 2016 , 22 Suppl 3, 1-203		557

1166	La Non Alcoholic Fatty Liver Disease (NAFLD) et la Non Alcoholic Steato-Hepatitis (NASH) des pathologies de syst�me : revue pour le r�animateur. 2016 , 26, 63	
1165	Antifibrotics in chronic liver disease: tractable targets and translational challenges. 2016 , 1, 328-340	22
1164	Novel Pharmacotherapy Options for NASH. 2016 , 61, 1398-405	27
1163	Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. 2016 , 65, 369-76	205
1162	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. 2016 , 59, 1121-40	275
1161	The liver in focus. 2016 , 59, 1095-7	1
1160	The metabolic vascular syndrome - guide to an individualized treatment. 2016 , 17, 5-17	25
1159	EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. 2016 , 9, 65-90	197
1158	Future Treatments of NASH. 2016 , 15, 125-133	2
1157	Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?. 2016 , 42, 142-56	59
1156	Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. 2016 , 2, 9	35
1155	Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. 2016 , 59, 1112-20	88
1154	Precision medicine: The future in diabetes care?. 2016 , 117, 12-21	32
1153	Non-alcoholic fatty liver disease and dyslipidemia: An update. 2016 , 65, 1109-23	212
1152	Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. 2016 , 45, 765-781	79
1151	Insulin degludec + liraglutide: a complementary combination. 2016 , 16, 1171-7	1
1150	Promising therapies for treatment of nonalcoholic steatohepatitis. 2016 , 21, 343-57	23
1149	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. 2016 , 1, 56-67	103

1148	Endoplasmic reticulum proteostasis in hepatic steatosis. 2016 , 12, 710-722	116
1147	Emerging and future therapies for nonalcoholic steatohepatitis in adults. 2016 , 17, 1937-46	29
1146	Non-alcoholic fatty liver disease in 2016. 2016 , 119, 143-56	51
1145	[Hepatic steatosis : Differential diagnostics and current aspects]. 2016 , 57, 879-92	1
1144	Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome. 2016 , 32, 329-334	23
1143	Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. 2016 , 59, 2588-2593	74
1142	Liraglutide for patients with non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2016 , 387, 2378	40 3
1141	NAFLD: The clinical and economic burden of NAFLD: time to turn the tide. 2016 , 13, 685-686	11
1140	Diabetestherapie bei nichtalkoholischer Fettlebererkrankung. 2016 , 12, 486-493	0
1139	Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. 2016 , 45, 639-652	117
1138	Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. 2016 , 8, 75-84	19
1137	Pharmacological Approaches for Nonalcoholic Fatty Liver Disease. 2016 , 23,	
1136	Pharmacological management of nonalcoholic fatty liver disease. 2016 , 65, 1183-95	70
1135	Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply. <i>Lancet, The</i> , 2016 , 387, 2379	40
1134	The Cardiovascular Biology of Glucagon-like Peptide-1. 2016 , 24, 15-30	311
1133	Entering the GOLDEN Age for Therapies in NASH. 2016 , 150, 1073-1076	3
1132	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor- α Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. 2016 , 150, 1147-1159.e5	629
1131	Management of NAFLD: a stage-based approach. 2016 , 13, 196-205	195

1130	Perspectives on Treatment for Nonalcoholic Steatohepatitis. 2016 , 150, 1835-48	55
1129	Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic. 2017 , 65, 2100-2109	77
1128	Response to: Drug therapy for ectopic fat: myth or reality?. 2017 , 15, 73-74	
1127	Non-alcoholic fatty liver disease and diabetes. 2017 , 148, 33-38	2
1126	Therapies in non-alcoholic steatohepatitis (NASH). 2017 , 37 Suppl 1, 97-103	129
1125	Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. 2017 , 41, 284-295	45
1124	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. 2017 , 49, 471-483	179
1123	Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. 2017 , 66, 180-190	260
1122	The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease. 2017 , 8, e217	34
1121	Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. 2017 , 40, 419-430	172
1120	Current and future treatment options in non-alcoholic steatohepatitis (NASH). 2017 , 11, 357-369	26
1119	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. 2017 , 71, 17-32	152
1118	Non-alcoholic fatty liver disease. 2017 , 15, 45	213
1117	Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. 2017 , 10, 535-547	13
1116	Current and future pharmacologic treatment of nonalcoholic steatohepatitis. 2017 , 33, 134-141	39
1115	GLP-1 receptor agonists in NAFLD. 2017 , 43 Suppl 1, 2S28-2S33	29
1114	Reversal of liver fibrosis: From fiction to reality. 2017 , 31, 129-141	79
1113	Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial. 2017 , 19, 1814-1817	51

1112	Targeting the gut-liver axis in liver disease. 2017 , 67, 1084-1103	199
1111	Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1. 2017 , 20, 300-309	10
1110	The Role of a Dedicated Non-Alcoholic Fatty Liver Disease Clinic in 2016. 2017 , 35, 371-376	6
1109	SIRT1/HSF1/HSP pathway is essential for exenatide-alleviated, lipid-induced hepatic endoplasmic reticulum stress. 2017 , 66, 809-824	45
1108	Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply. 2017 , 5, 330	0
1107	An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia. 2017 , 11, 759-772	9
1106	Management of obesity in adult Asian Indians. 2017 , 69, 539-544	33
1105	The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus. 2017 , 8, 218-227	13
1104	Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies. 2017 , 7, 3255	41
1103	Treatment of NAFLD with diet, physical activity and exercise. 2017 , 67, 829-846	492
1102	Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. 2017 , 37, 1887-1896	37
1101	A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist. 2017 , 12, 2107-2116	15
1100	Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. 2017 , 13, 625-640	14
1099	Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. 2017 , 71, 182-197	73
1098	Non-alcoholic fatty liver disease and diabetes. 2017 , 148, 33-38	
1097	De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. 2017 , 21, 321-335	13
1096	The Metabolic Syndrome, Oxidative Stress, and the Liver. 2017 , 323-329	1
1095	Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. 2017 , 9, 800-809	69

1094	Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. 2017 , 3, CD011640	28
1093	Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus. 2017 , 47, 1206-1211	46
1092	Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. 2017 , 47, 266-280	44
1091	EndoBarrier Gastrointestinal Liner in Type 2 Diabetic Patients Improves Liver Fibrosis as Assessed by Liver Elastography. 2017 , 125, 116-121	8
1090	Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?. 2017 , 49, 235-240	29
1089	Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs. 2017 , 31, 521-522	24
1088	Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. 2017 , 28, 250-260	155
1087	Non-alcoholic Fatty Liver Disease. 2017 , 111-129	1
1086	Overview of Clinical Treatment Trials for NASH. 2017 , 16, 366-373	
1085	Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study. 2017 , 8, 1297-1308	10
1084	Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. 2017 , 6, 1360-1370	34
1083	Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: From bench to bedside. 2017 , 10, 32-35	3
1082	Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. 2017 , 136, 849-870	279
1081	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. 2017 , 29, 185-200	
1080	Regulation of hepatic glucose metabolism in health and disease. 2017 , 13, 572-587	421
1079	Inhibition of exendin-4-induced steatosis by protein kinase A in cultured HepG2 human hepatoma cells. 2017 , 53, 721-727	0
1078	GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice. 2017 , 31, 1370-1375	2
1077	Review article: new treatments in non-alcoholic fatty liver disease. 2017 , 46, 494-507	41

1076	Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase. 2017 , 31, 1630-1637	17
1075	Non-alcoholic fatty liver disease: A poorly known pandemic. 2017 , 149, 542-548	17
1074	The pharmacological management of NAFLD in children and adolescents. 2017 , 10, 1225-1237	9
1073	Non-alcoholic fatty liver disease: A poorly known pandemic. 2017 , 149, 542-548	0
1072	How to Approach a Patient With Nonalcoholic Fatty Liver Disease. 2017 , 153, 345-349	5
1071	Treatment options for nonalcoholic steatohepatitis - a safety evaluation. 2017 , 16, 903-913	18
1070	MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. 2017 , 177, R145-R158	21
1069	Mouse models of nonalcoholic steatohepatitis in preclinical drug development. 2017 , 22, 1707-1718	107
1068	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. 2017 , 18, 1243-1260	30
1067	Nonalcoholic fatty liver disease: implications for cardiovascular risk. 2017 , 6, 62-72	7
1066	Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. 2017 , 66, 123-131	202
1065	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. 2017 , 29, 185-200	6
1064	Effects of Liraglutide and Vitamin E in Fructose-Induced Metabolic Syndrome in Rats. 2017 , 99, 48-56	6
1063	NAFLD and diabetes mellitus. 2017 , 14, 32-42	434
1062	The therapeutic landscape of non-alcoholic steatohepatitis. 2017 , 37, 634-647	26
1061	Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. 2017 , 65, 350-362	301
1060	A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice. 2017 , 65, 950-968	49
1059	Nonalcoholic Fatty Liver Disease. 2017 , 867-908	1

1058	Particularités des diabètes associés aux maladies hépatiques. 2017 , 11, 682-686	2
1057	Traitement de la stéatose et de la stéatohépatite non alcoolique par les traitements antidiabétiques. 2017 , 11, 697-701	2
1056	Therapies for non-alcoholic steatohepatitis. 2017 , 1, 214-220	1
1055	Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. 2017 , 64, 269-281	54
1054	miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1. 2017 , 23, 8140-8151	39
1053	Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice. 2017 , 8, 294	12
1052	Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. 2017 , 9,	220
1051	Adipose tissue, obesity and non-alcoholic fatty liver disease. 2017 , 42, 92-108	79
1050	[Treatment Options in Non-alcoholic Fatty Liver Disease]. 2017 , 69, 353-358	3
1049	Prevalence, etiology and management of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome. 2017 , 42, 122-131	8
1048	Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne. 2017 , 42, 109-121	8
1047	Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease. 2017 , 42, 184-194	13
1046	Nonalcoholic fatty liver disease: Evolving paradigms. 2017 , 23, 6571-6592	92
1045	Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. 2017 , 135, 277-295	19
1044	The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin. 2017 , 56, 2739-2744	25
1043	Non-alcoholic Fatty Liver Disease: A Clinical Update. 2017 , 5, 384-393	69
1042	Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. 2017 , 23, 7495-7504	34
1041	Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. 2017 , 23, 6549-6570	112

1040	Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. 2017 , 23, 141-150	90
1039	Nonalcoholic Steatohepatitis. 2018 , 378, 781	11
1038	Cardiometabolic Effects of Anti-obesity Pharmacotherapy. 2018 , 20, 18	5
1037	The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). 2018 , 17, 219-229	31
1036	Obesity and Nonalcoholic Fatty Liver Disease. 2018 , 89-97	1
1035	Targeting GLP-1 receptor trafficking to improve agonist efficacy. 2018 , 9, 1602	88
1034	Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment. 2018 , 58, 1314-1323	41
1033	Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies Treatment. 2018 , 5, 255-258	7
1032	Current treatment for non-alcoholic fatty liver disease. 2018 , 83, 125-133	5
1031	Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis. 2018 , 12, 97-106	14
1030	Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. 2018 , 27, 740-756	441
1029	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. 2018 , 41, 328-349	30
1028	Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. 2018 , 58, 28-36	21
1027	Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. 2018 , 8, 2362	72
1026	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. 2018 , 13, 321-350	234
1025	Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. 2018 , 35, 218-231	8
1024	Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. 2018 , 15, 467-479	111
1023	Newer GLP-1 receptor agonists and obesity-diabetes. 2018 , 100, 61-67	29

1022	Future therapy for non-alcoholic fatty liver disease. 2018 , 38 Suppl 1, 56-63	33
1021	Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. 2018 , 9, 15-28	22
1020	What have we learnt from "real world" data, observational studies and meta-analyses. 2018 , 20 Suppl 1, 47-58	32
1019	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. 2018 , 14, 99-114	170
1018	Current and future pharmacological therapies for NAFLD/NASH. 2018 , 53, 362-376	306
1017	Peri-operative management of patients with type-2 diabetes mellitus undergoing non-cardiac surgery using liraglutide, glucose-insulin-potassium infusion or intravenous insulin bolus regimens: a randomised controlled trial. 2018 , 73, 332-339	21
1016	Glucagon-like peptide 1 in health and disease. 2018 , 14, 390-403	187
1015	Precision medicine in the management of type 2 diabetes. 2018 , 6, 891-900	60
1014	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. 2018 , 15, 425-439	114
1013	Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis. 2018 , 11, 87-91	9
1012	New antihyperglycaemic agents and cardiovascular disease: let's be optimistic. 2018 , 33, 444-454	3
1011	Diabetes and NAFLD. 2018 , 1-27	
1010	[Therapy of nonalcoholic steatohepatitis: the proven and the new]. 2018 , 160, 50-54	1
1009	WITHDRAWN: Nonalcoholic steatohepatitis therapies. 2018 ,	
1008	New therapeutic perspectives in non-alcoholic steatohepatitis. 2018 , 41, 128-142	
1007	Therapeutic application of GPR119 ligands in metabolic disorders. 2018 , 20, 257-269	29
1006	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. 2018 , 67, 328-357	2641
1005	Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. 2018 , 20, 215-218	55

1004	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. 2018 , 33, 86-98	71
1003	Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. 2018 , 22, 189-199	19
1002	Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies. 2018 , 58, 649-662	40
1001	Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option. 2018 , 66, 7-10	36
1000	Progress and challenges in anti-obesity pharmacotherapy. 2018 , 6, 237-248	118
999	New therapeutic perspectives in non-alcoholic steatohepatitis. 2018 , 41, 128-142	8
998	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. 2018 , 41, 341-347	56
997	Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. 2018 , 1864, 607-617	26
996	NAFLD/NASH in patients with type 2 diabetes and related treatment options. 2018 , 41, 509-521	32
995	Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. 2018 , 68, 361-371	197
994	Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?. 2018 , 19, 185-187	4
993	Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography. 2018 , 47, 504-515	27
992	Pharmacotherapy for NASH: Current and emerging. 2018 , 68, 362-375	160
991	Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. 2018 , 47, 268-278	26
990	Metabolic Effects of Bariatric Surgery. 2018 , 64, 72-81	16
989	Lipotoxicity and the gut-liver axis in NASH pathogenesis. 2018 , 68, 280-295	324
988	Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?. 2018 , 10, 790-794	17
987	Diabetes mellitus and liver disease. 2018 , 3, 93-93	

986	Effizienz antidiabetischer Kombinationstherapien bei nichtalkoholischer Fettlebererkrankung und Typ-2-Diabetes. 2018 , 14, 601-602	
985	Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease. 2018 , 19, 88	1
984	Full Issue PDF. 2018 , 3, I-CLVIII	
983	Managing diabetes and liver disease association. 2018 , 19, 166-179	11
982	Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy. 2018 , 8, 16461	6
981	Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. 2018 , 11,	26
980	Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. 2018 , 6, 264-275	33
979	Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications. 2018 , 33, 665-675	5
978	Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. 2018 , 38,	30
977	Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. 2018 , 11, 1756284818811508	12
976	Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. 2018 , 9, 649	43
975	Diagnosis and Management of Nonalcoholic Fatty Liver Disease. 2018 , 320, 2474-2475	23
974	Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis. 2018 , 67, 2485-2493	52
973	The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE and LDLr Mice by a Mechanism That Includes Inflammatory Pathways. 2018 , 3, 844-857	108
972	Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. 2018 , 18, 165	19
971	[Non-alcoholic fatty liver disease - a summary and update based on the EASL-EASD-EASO Clinical Practice Guidelines of 2016]. 2018 , 159, 1815-1830	1
970	Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. 2018 , 14, 1233-1244	26
969	The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis. 2018 , 79, 694-699	8

968	GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols. 2018 , 59, 349-360	6
967	Editorial: Arterial Stiffness, Central Haemodynamics and Non-Alcoholic Fatty Liver Disease: Links with Cardiovascular Risk and Effects of Drug Treatment. 2018 , 16, 401-404	10
966	Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. 2019 , 34, 1396-1403	33
965	Advances in therapeutic options for portal hypertension. 2018 , 11, 1756284818811294	16
964	Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. 2018 , 6,	12
963	Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. 2018 , 25, 315-320	5
962	Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. 2018 , 48, 1109-1116	53
961	Obesity and nonalcoholic fatty liver disease: current perspectives. 2018 , 11, 533-542	85
960	Advances in Pediatric Fatty Liver Disease: Pathogenesis, Diagnosis, and Treatment. 2018 , 47, 949-968	10
959	Circular RNAs in Metabolic Diseases. 2018 , 1087, 275-285	13
958	An update on the recent advances in antifibrotic therapy. 2018 , 12, 1143-1152	45
957	Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis. 2018 , 24, 2468-2481	36
956	When to Initiate Weight Loss Medications in the NAFLD Population. 2018 , 6,	7
955	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. 2018 , 69, 1155-1163	25
954	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. 2018 , 19, 1903-1914	10
953	Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. 2018 , 19,	12
952	Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 2018 , 137, 219-229	35
951	Unfolded Protein Response Sensors in Hepatic Lipid Metabolism and Nonalcoholic Fatty Liver Disease. 2018 , 38, 320-332	14

950 Management of Nonalcoholic Fatty Liver Disease (NAFLD). **2018,**

949 A systematic review of the present and future of non-alcoholic fatty liver disease. **2018, 4, 165-174** 30

948 Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. **2018, 94, 556-565** 11

947 Effect of saxagliptin on the expression of HIF-1 α in the liver of diabetic rats with fatty liver. **2018, 16, 2559-2563** 3

946 Metabolic Surgery, Reality or Myth: Scientific Side of Obesity Pathophysiology and Management. **2018, 403-414**

945 Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches. **2018, 9, 485** 30

944 Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer. **2018, 15, 606-624** 43

943 Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. **2018, 30, 1103-1115** 33

942 Characteristics of WBN/Kob diabetic fatty rats supplemented with a fructose-rich diet as a metabolic syndrome model: response to a GLP-1 receptor agonist. **2018, 80, 1515-1523** 2

941 Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease. **2018,** 3

940 SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. **2018, 44, 493-499** 24

939 NAFLD and cardiovascular disease. **2018, 3, e2** 2

938 Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. **2018, 41, 328-349** 1

937 Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus. **2018, 9, 1369-1375** 2

936 Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. **2018, 63, 2259-2266** 19

935 Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. **2018, 28, 23-32.e3** 49

934 Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus. **2018, 142, 254-263** 35

933 Mechanisms of NAFLD development and therapeutic strategies. **2018, 24, 908-922** 1110

932	Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. 2018 , 75, 3313-3327	367
931	Treatment of Diabetic Mice with a Combination of Ketogenic Diet and Aerobic Exercise via Modulations of PPARs Gene Programs. 2018 , 2018, 4827643	11
930	Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis. 2018 , 123, 704-713	31
929	Current Prevention and Treatment Options for NAFLD. 2018 , 1061, 149-157	10
928	Obesity, Fatty Liver and Liver Cancer. 2018 ,	3
927	Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. 2018 , 33, 197-210	2
926	Inflammation and Metabolic Complications in HIV. 2018 , 15, 371-381	18
925	Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME [®] trial. 2018 , 61, 2155-2163	100
924	Recent advances in understanding and managing non-alcoholic fatty liver disease. 2018 , 7,	32
923	Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. 2018 , 6, 168-174	18
922	Quality of life in patients with nonalcoholic fatty liver disease: A systematic review. 2018 , 112, 73-80	18
921	Effects of isomaltulose on insulin resistance and metabolites in patients with non-alcoholic fatty liver disease: A metabolomic analysis. 2018 , 18, 2033-2042	5
920	Nichtalkoholische Fettleber – eine unterschätzte Erkrankung?. 2018 , 18, 32-38	
919	SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. 2018 , 41, 1543-1556	99
918	Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. 2018 , 17, 48	22
917	Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. 2018 , 20, 315-329	16
916	Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5). 2018 , 61, 7589-7613	18
915	Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. 2018 , 24, 3361-3373	203

914	The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications. 2018 , 67, 1710-1719	50
913	Burden of non-alcoholic fatty liver disease in Australia. 2018 , 33 Suppl 1, 1-11	25
912	Molecular Basis of Liver Disease. 2018 , 417-456	
911	Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. 2018 , 35, 1434-1439	39
910	Non-alcoholic fatty liver disease and the interface between primary and secondary care. 2018 , 3, 509-517	64
909	Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes. 2018 , 2, 778-785	22
908	Current treatment for non-alcoholic fatty liver disease. 2018 , 83, 125-133	2
907	Clinical pharmacology of glucagon-like peptide-1 receptor agonists. 2018 , 17, 333-350	26
906	Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). 2018 , 41, 1801-1808	244
905	Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. 2019 , 21, 84-94	41
904	Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease. 2019 , 39, 122-127	1
903	Lean non-alcoholic fatty liver disease. 2019 , 38, 975-981	43
902	Simulation of gastric bypass effects on glucose metabolism and non-alcoholic fatty liver disease with the Sleeveballoon device. 2019 , 46, 452-462	8
901	Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study. 2019 , 73, e13399	24
900	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. 2019 , 17, 425-428	4
899	The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease. 2019 , 203, 107401	47
898	NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. 2019 , 10, 877	43
897	Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. 2019 , 13, 849-866	24

896	A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients. 2019 , 18, 87	21
895	Who Should Treat Fatty Liver Disease: Primary Care or Hepatology?. 2019 , 13, 158-161	
894	Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. 2019 , 17, 2769-2775.e4	19
893	Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. 2019 , 70, 1424-1436	44
892	Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. 2019 , 71, 823-833	64
891	Obesity and Hepatocarcinogenesis. 2019 , 87-102	
890	Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort. 2019 , 9, 9996	3
889	From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. 2019 , 1, 312-328	116
888	Reversal of NASH fibrosis with pharmacotherapy. 2019 , 13, 534-545	10
887	Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. 2019 , 10, 1645-1717	17
886	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. 2019 , 50, 193-203	62
885	Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease. 2019 , 9, 723-730	22
884	Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. 2019 , 179, 1262-1271	93
883	SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. 2019 , 12, 1001-1012	15
882	NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?. 2019 , 30, 891-902	42
881	Hepatic steatosis in patients undergoing resection of colorectal liver metastases: A target for prehabilitation? A narrative review. 2019 , 30, 147-158	5
880	Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy. 2019 , 864, 172715	49
879	Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. 2019 , 101, 154001	37

878	Personalized Management of Type 2 Diabetes. 2019 , 19, 115		3
877	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. 2019 , 16,		12
876	Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2019 , 394, 2012-2024	40	193
875	Magnetic-Assisted Treatment of Liver Fibrosis. 2019 , 8,		13
874	Liraglutide for non-alcoholic fatty liver disease in children and adolescents: has a new era arrived?. 2019 , 14, 221-222		
873	Editorial: it is not a wide-open field for incretins - collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis. 2019 , 50, 611-612		
872	Mastiha (<i>Pistacia lentiscus</i>) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy-Confirmed Mouse Model of Advanced Non-Alcoholic Steatohepatitis and Fibrosis. 2019 , 63, e1900927		12
871	Das Leben und das Essen trotz nichtalkoholischer Fettleber genießen. 2019 , 13, 30-40		
870	Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis. 2019 , 317, G508-G517		4
869	Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. 2019 , 16,		81
868	Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways. 2019 , 861, 172594		22
867	Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons - Implications for energy balance and glucose control. 2019 , 28, 120-134		27
866	Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis. 2019 , 4, 53		17
865	Effect of glucagon-like peptide-1 analogue liraglutide on primary cultures of rat hepatocytes isolated from lean and steatotic livers. 2019 , 38, 343-352		
864	PROs of Patient-reported Outcomes for Nonalcoholic Fatty Liver Disease and Effects on Treatment for Nonalcoholic Steatohepatitis. 2019 , 17, 1950-1953		1
863	Liver and insulin resistance: New wine in old bottle!!!. 2019 , 862, 172657		20
862	A comprehensive approach to type 2 diabetes mellitus [A recommendation document]. 2019 , 66, 443-458		1
861	Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. 2019 , 6, 202		55

860	The new liver epidemic. 2019 , 37, 209-214	6
859	TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. 2019 , 8,	6
858	New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. 2019 , 49, 60-70	33
857	Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease. 2019 , 30, 903-914	49
856	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. 2019 , 16,	43
855	Effects of duodenal-jejunal bypass surgery in ameliorating nonalcoholic steatohepatitis in diet-induced obese rats. 2019 , 12, 149-159	4
854	Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies. 2019 , 34, e14	2
853	Management of diabetes mellitus in patients undergoing liver transplantation. 2019 , 141, 556-573	14
852	Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. 2019 , 282, 110-120	45
851	Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR- γ) agonist and a glucagon-like peptide-1 analogue. 2019 , 111, 926-933	9
850	Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. 2019 , 103, 28-38	16
849	Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. 2019 , 103, 57-67	36
848	The Mexican consensus on nonalcoholic fatty liver disease. 2019 , 84, 69-99	15
847	Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease. 2019 , 55,	22
846	The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. 2019 , 28, 18-29	9
845	Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. 2019 , 42, 1481-1488	105
844	Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway. 2019 , 2019, 1567095	9
843	Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection?. 2019 , 70, 581-583	11

842	Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People. 2019 , 17, 303-313	3
841	A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH). 2019 , 7, e00485	11
840	Alcoholic/Non-Alcoholic Digestive Diseases. 2019 ,	
839	Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial). 2019 , 21, 2305-2314	5
838	Mitochondria-Mediated Pathogenesis and Therapeutics for Non-Alcoholic Fatty Liver Disease. 2019 , 63, e1900043	20
837	Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease. 2019 , 34, 2011-2018	22
836	Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution. 2019 ,	1
835	Metabolic Targets in Nonalcoholic Fatty Liver Disease. 2019 , 8, 247-267	48
834	Diagnosis and management of non-alcoholic fatty liver disease. 2019 , 95, 314-322	40
833	Nicht alkoholische Fettlebererkrankung (NAFLD) Ursachen, Diagnostik, Therapie. 2019 , 15, 27-37	
832	Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. 2019 , 20,	72
831	Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. 2019 , 43, 127-143	23
830	Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. 2019 , 69, 2318-2322	21
829	Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. 2019 , 17, 377-387	6
828	A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. 2019 , 10, 337-346	22
827	Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. 2019 , 57, 508-517	26
826	Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders. 2019 , 245-274	
825	Nonalcoholic Fatty Liver Disease and Steatohepatitis in Children. 2019 , 279-291	

824	Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. 2019 , 70, 1443-1456	8
823	The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. 2019 , 6,	46
822	Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. 2019 , 36, 1052-1074	37
821	Current Management Strategy of Non-Alcoholic Fatty Liver Disease. 2019 , 9, 46-56	
820	Inhibition of microRNA-124a attenuates non-alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide intervention. 2019 , 49, 743-757	11
819	Animal Models of Type 2 Diabetes, Obesity and Nonalcoholic Steatohepatitis [Clinical Translatability and Applicability in Preclinical Drug Development. 2019 , 369-403	2
818	Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis. 2019 , 20,	37
817	The Mexican consensus on nonalcoholic fatty liver disease. 2019 , 84, 69-99	1
816	Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. 2019 , 73, 948-963	135
815	Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo. 2019 , 10, 924	24
814	Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. 2019 , 39, 941-949	31
813	[Metabolic surgery]. 2019 , 90, 157-170	1
812	Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. 2019 , 45, 213-223	68
811	The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. 2019 , 79, 231-242	8
810	The Discovery and Development of Liraglutide and Semaglutide. 2019 , 10, 155	181
809	Nonalcoholic Fatty Liver Disease. 2019 , 523-546	
808	The Liver Before and After Bariatric Surgery. 2019 , 39-58	
807	Semaglutide as a promising antiobesity drug. 2019 , 20, 805-815	33

806	How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. 2019 , 171, 199-207	2
805	4. Comprehensive Medical Evaluation and Assessment of Comorbidities:. 2019 , 42, S34-S45	120
804	Document on a comprehensive approach to type 2 diabetes mellitus. 2019 , 66, 443-458	13
803	Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. 2019 , 19, 175-185	9
802	Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. 2019 , 8, 295	25
801	A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis. 2019 , 11, 159-178	17
800	Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article. 2019 , 20, 189-197	1
799	[Pharmacological treatment of NASH]. 2019 , 48, 1489-1495	
798	Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. 2019 , 19, 228	5
797	Current treatment options for nonalcoholic fatty liver disease. 2019 , 35, 168-176	13
796	Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. 2019 , 114, 579-590	14
795	Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. 2019 , 7, 313-324	322
794	International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. 2019 , 103, 45-56	42
793	Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. 2019 , 21, 293-302	40
792	Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. 2019 , 1864, 326-334	5
791	Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. 2019 , 79, 75-84	13
790	Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. 2019 , 70, 711-724	112
789	Derivation and Performance of Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the Detection and Prognosis of Liver Fibrosis. 2019 , 3, 815-826	14

788	Hepatic microcirculation and mechanisms of portal hypertension. 2019 , 16, 221-234	77
787	Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. 2019 , 6, 1801585	66
786	Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice. 2019 , 316, G412-G424	43
785	Obesity and cardiovascular disease: revisiting an old relationship. 2019 , 92, 98-107	183
784	The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. 2019 , 16, 145-159	284
783	Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. 2019 , 20, 69-82	15
782	Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). 2019 , 20, 163-173	47
781	Clinical Aspects of Alcoholic Liver Disease. 2019 , 3-21	
780	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. 2019 , 21, 812-821	65
779	The Future of Nonalcoholic Fatty Liver Disease Treatment. 2019 , 103, 57-69	11
778	Steatosis in Liver Transplantation: Current Limitations and Future Strategies. 2019 , 103, 78-90	41
777	Obesity and NAFLD. 2019 , 179-194	1
776	NASH in Lean Individuals. 2019 , 39, 86-95	77
775	Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. 2019 , 69, 2414-2426	86
774	Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease. 2019 , 160, 34-45	29
773	Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research. 2019 , 100, 79-85	14
772	Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. 2019 , 17, 1040-1060.e11	135
771	Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. 2019 , 92, 82-97	270

770	Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease. 2019 , 39, 250-256	22
769	Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. 2020 , 71, 495-509	71
768	NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis. 2020 , 71, 1198-1212	129
767	Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. 2020 , 65, 623-631	65
766	Fat and Fibrosis: Does Empagliflozin Impair the Progression of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus?. 2020 , 65, 342-344	3
765	Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). 2020 , 29, 117-123	29
764	Multi-drug approaches to NASH: what's in the development pipeline?. 2020 , 29, 143-150	12
763	Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease. 2020 , 59, 329-338	1
762	Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors. 2020 , 63, 905-927	14
761	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. 2020 , 41,	56
760	Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. 2020 , 72, 401-410	21
759	Nonalcoholic Steatohepatitis After Liver Transplantation. 2020 , 26, 141-159	16
758	Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease. 2020 , 133, 170-177	14
757	Liver Disease, Nonalcoholic Fatty. 2020 , 408-413	0
756	Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. 2020 , 63, 65-74	27
755	Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes. 2020 , 40, 308-318	2
754	Development of new drugs for the treatment of nonalcoholic steatohepatitis. 2020 , 21, 3-11	7
753	Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. 2020 , 22, 393-403	30

752	Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. 2020 , 63, 253-260	45
751	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. 2020 , 63, 5031-5073	35
750	Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice. 2020 , 44, 937-947	3
749	Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. 2020 , 29, 125-133	20
748	High rates of ineligibility for participation in trials of new therapies in non-alcoholic steatohepatitis: a systematic review. 2020 , 32, 1023-1029	2
747	Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. 2020 , 46, 427-441	42
746	Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. 2020 , 3, e00105	10
745	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. 2020 , 49, 141-149	9
744	The molecular basis for current targets of NASH therapies. 2020 , 29, 151-161	8
743	Evolution of NAFLD and Its Management. 2020 , 35, 72-84	61
742	Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. 2020 , 104, 154045	12
741	Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. 2020 , 55, 142-158	41
740	Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. 2020 , 38, 377-386	3
739	New drugs for NAFLD: lessons from basic models to the clinic. 2020 , 14, 8-23	24
738	Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. 2020 , 46, 296-303	21
737	A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. 2020 , 8,	3
736	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. 2020 , 97, 106174	8
735	Glucagon Like Peptide-1 Receptor Agonists Alter Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model. 2021 , 129, 625-633	3

734	Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. 2020 ,	5
733	Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. 2020 , 24, 549-576	4
732	Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review. 2020 , 12, 139-151	7
731	Cardiovascular risk, Metabolic disease and NASH control for Health Empowerment: Future endeavours. 2020 , 32, 206-208	
730	Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. 2020 , 19, 674-690	24
729	Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis. 2020 , 1, 100056	13
728	One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. 2020 , 9,	2
727	Non-Alcoholic Fatty Liver Disease. 2020 ,	1
726	Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. 2020 , 20, 59	18
725	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. 2020 , 14, 889-919	142
724	Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. 2021 , 19, 2274-2283.e5	22
723	Dysregulated lipid metabolism links NAFLD to cardiovascular disease. 2020 , 42, 101092	45
722	NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. 2020 , 12, 60	104
721	Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. 2020 , 9,	28
720	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?. 2020 , 21,	6
719	Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. 2020 , 215, 107626	7
718	Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. 2021 , 50, 101049	12
717	AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis. 2020 , 11, 5807	21

7 ¹⁶	Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells. 2020 , 21,	13
7 ¹⁵	NAFLD and liver transplantation: Disease burden, current management and future challenges. 2020 , 2, 100192	26
7 ¹⁴	Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. 2021 , 50, 101122	23
7 ¹³	Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. 2020 , 11, 597583	14
7 ¹²	Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes. 2020 , 14, 2233-2239	5
7 ¹¹	The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders. 2020 , 9,	17
7 ¹⁰	Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root. 2020 , 19, 302-314	
7 ⁰⁹	Stratification of patients in NASH clinical trials: A pitfall for trial success. 2020 , 2, 100148	9
7 ⁰⁸	The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight. 2020 , 375, 21-27	8
7 ⁰⁷	The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. 2020 , 2, 100168	7
7 ⁰⁶	A New Treatment for Chronic Hepatitis B and D Offers Novel Insights Into Obesity and Hepatic Steatosis. 2020 , 10, 649-651	1
7 ⁰⁵	[New oral antidiabetic drugs]. 2020 , 45, 493-503	
7 ⁰⁴	Liver disease. 2020 , 483-502	0
7 ⁰³	Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis. 2020 , 21,	4
7 ⁰²	4. Comprehensive Medical Evaluation and Assessment of Comorbidities:. 2020 , 43, S37-S47	114
7 ⁰¹	Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. 2020 , 14, 1913-1919	3
7 ⁰⁰	Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection. 2020 , 9, 391-401	3
6 ⁹⁹	Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index. 2020 , 4, 995-1001	4

698	A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?. 2020 , 22, 2227-2240	8
697	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. 2020 , 142, 1205-1218	16
696	The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). 2020 , 2020, 3920196	40
695	Utilizing Designed Receptors Exclusively Activated by Designer Drug Chemogenetic Tools to Identify Beneficial G Protein-Coupled Receptor Signaling for Fibrosis. 2020 , 375, 357-366	2
694	Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). 2020 , 63, 2434-2445	46
693	PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide. 2020 , 70, 517-525	2
692	High-Risk Groups for Non-alcoholic Fatty Liver and Non-alcoholic Steatohepatitis Development and Progression. 2020 , 19, 412-419	4
691	Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. 2020 , 3, e00179	5
690	Current and Emerging Treatments for Non-alcoholic Steatohepatitis. 2020 , 19, 391-401	2
689	Nichtalkoholische Fettlebererkrankung und Typ-2-Diabetes. 2020 , 16, 574-583	
688	Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. 2020 , 21,	20
687	Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway. 2020 , 8, 602574	19
686	Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. 2020 , 21,	14
685	Control del riesgo cardiovascular, la enfermedad metabólica y la esteatosis hepática a través del empoderamiento de la salud: una propuesta de futuro. 2020 , 32, 206-208	1
684	Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart. 2020 , 31, 364-366	6
683	Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting. 2020 , 3, e00131	3
682	Ezetimibe Markedly Reduces Hepatic Triglycerides and Cholesterol in Rats Fed on Fish Oil by Increasing the Expression of Cholesterol Efflux Transporters. 2020 , 374, 175-183	3
681	Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. 2020 , 69, 1877-1884	54

680	Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis. 2020 , 36, 411-416	2
679	Insights into incretin-based therapies for treatment of diabetic dyslipidemia. 2020 , 159, 34-53	11
678	[New pharmacological treatment options for nonalcoholic fatty liver disease]. 2020 , 61, 759-765	
677	Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. 2020 , 2, 413-431	47
676	Les nouveaux traitements de la stéatohépatite non-alcoolique. 2020 , 34, 216-222	3
675	Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?. 2020 , 6, 9	25
674	Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. 2020 , 21, 1637-1650	19
673	Metabolic liver disease in diabetes - From mechanisms to clinical trials. 2020 , 111S, 154299	39
672	Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist. 2020 , 25,	1
671	Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. 2020 , 159, 104984	9
670	Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. 2020 , 3, e00163	21
669	Effects and Safety of Sitagliptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. 2020 , 52, 517-526	3
668	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. 2020 , 21,	22
667	Nonalcoholic Fatty Liver Disease. 2020 , 1	2
666	Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet. 2020 , 2020, 2947549	7
665	Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. 2020 , 111S, 154203	46
664	Treatment of non-alcoholic fatty liver disease - Current perspectives. 2020 , 39, 22-31	9
663	Glucagon-based therapy: Past, present and future. 2020 , 127, 170296	8

662	Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. 2020 , 22, 1328-1338	15
661	Nonalcoholic Steatohepatitis: A Review. 2020 , 323, 1175-1183	254
660	The Effect of Moderate Weight Loss on a Non-Invasive Biomarker of Liver Fibrosis: A Randomised Controlled Trial. 2020 , 13, 144-151	2
659	Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. 2020 , 44, 674-680	22
658	Diabetestherapie bei nichtalkoholischer Fettlebererkrankung und Leberzirrhose. 2020 , 15, 96-105	
657	Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management. 2020 , 19, 315-326	2
656	The hepatic lipidome: From basic science to clinical translation. 2020 , 159, 180-197	15
655	Approach to prevention of non-alcoholic fatty liver disease after liver transplantation. 2020 , 5, 51	5
654	Exploring Therapeutic Targets to Reverse or Prevent the Transition from Metabolically Healthy to Unhealthy Obesity. 2020 , 9,	8
653	Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease: a Korean nationwide survey. 2020 , 11, 1232-1241	11
652	Efficacy and safety of incretin-based therapies in patients with nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis. 2020 , 99, e20695	
651	Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. 2020 , 52, 619-636	4
650	Diabetes: From Research to Clinical Practice. 2021 , 1307, 1-5	4
649	Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes. 2020 , 36, 527-547	3
648	Bariatric Surgery is Associated With Decreased Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis: A Retrospective Cohort Analysis. 2020 , 272, 32-39	18
647	Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. 2020 , 37, 1793-1806	5
646	The Emerging Epidemic of Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: True, True, and Related?. 2020 , 65, 1885-1887	4
645	Development and Validation of a Scoring System, Based on Genetic and Clinical Factors, to Determine Risk of Steatohepatitis in Asian Patients with Nonalcoholic Fatty Liver Disease. 2020 , 18, 2592-2599. ¹⁶	10

644	A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. 2020 , 40 Suppl 1, 82-88	18
643	Current management of non-alcoholic steatohepatitis. 2020 , 40 Suppl 1, 89-95	24
642	Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. 2020 , 49, 105-121	1
641	Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. 2020 , 126, 679-704	58
640	Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. 2020 , 11, 70	14
639	Therapeutic Landscape for NAFLD in 2020. 2020 , 158, 1984-1998.e3	59
638	New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. 2020 , 71, 1831-1844	10
637	[What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?]. 2020 , 58, 68-73	2
636	Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes. 2020 , 43, 275-279	25
635	Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes. 2020 , 34, 16-26	9
634	Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. 2020 , 36, e3292	27
633	Fatty liver in pregnancy: a narrative review of two distinct conditions. 2020 , 14, 127-135	8
632	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. 2020 , 18, 172-181	24
631	The Kidney in Liver Disease. 2020 , 630-644	1
630	Non-alcoholic Fatty Liver Disease. 2020 , 670-681	1
629	Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?. 2020 , 133, 536-543	25
628	AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. 2020 , 158, 1822-1830	94
627	[Non-alcoholic fatty liver disease (NAFLD)]. 2020 , 162, 56-62	1

626	Current and new pharmacotherapy options for non-alcoholic steatohepatitis. 2020 , 21, 953-967	17
625	Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. 2020 , 43, 1352-1355	64
624	Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. 2020 , 73, 680-693	32
623	Rebaudioside affords hepatoprotection ameliorating sugar sweetened beverage- induced nonalcoholic steatohepatitis. 2020 , 10, 6689	8
622	NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. 2020 , 69, 1691-1705	118
621	The limits and challenges of antiobesity pharmacotherapy. 2020 , 21, 1319-1328	9
620	Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. 2021 , 19, 146-154.e4	32
619	A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. 2021 , 55, 65-79	26
618	Evolving Role for Pharmacotherapy in NAFLD/NASH. 2021 , 14, 11-19	28
617	Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real-time two-dimensional shear wave elastography: A randomized clinical trial. 2021 , 35, 1669-1679	10
616	The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. 2021 , 227, 75-88	19
615	NAFLD in type 2 diabetes mellitus: Still many challenging questions. 2021 , 37, e3386	5
614	Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. 2021 , 53, 44-51	15
613	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. 2021 , 18, 24-39	67
612	Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. 2021 , 16, 125-134	0
611	Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease. 2021 , 94, 183-192	5
610	Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential. 2021 , 73, 2051-2062	1
609	Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery. 2021 , 106, 750-761	1

608	Immunological mechanisms and therapeutic targets of fatty liver diseases. 2021 , 18, 73-91	25
607	Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. 2021 , 41, 982-995	5
606	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. 2021 , 384, 1113-1124	244
605	A review of non-alcoholic fatty liver disease in non-obese and lean individuals. 2021 , 36, 1497-1507	10
604	Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. 2021 , 45, 101568	1
603	NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. 2021 , 47, 101215	29
602	The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. 2021 , 115, 154455	22
601	4. Comprehensive Medical Evaluation and Assessment of Comorbidities:. 2021 , 44, S40-S52	57
600	Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. 2021 , 42, 101-132	34
599	The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. 2021 , 893, 173823	2
598	Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. 2021 , 46, 101153	2
597	Safety and efficacy of pharmacologic weight loss in patients with cirrhosis. 2021 , 7, 159-167	1
596	GLP-1-Analoga in der Therapie des Typ-2-Diabetes bei Jugendlichen. 2021 , 169, 253-257	
595	Was bedeuten die neuen Diabetessubgruppen für Menschen mit Fettlebererkrankung?. 2021 , 17, 20-25	1
594	AGA Clinical Practice Update on Bariatric Surgery in Cirrhosis: Expert Review. 2021 , 19, 436-445	10
593	Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?. 2021 , 15, 51-64	3
592	Lean NAFLD: an underrecognized and challenging disorder in medicine. 2021 , 22, 351-366	5
591	Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry. 2021 , 6, 5	2

590	Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. 2021 , 11,	50
589	Liraglutide-Induced Hepatotoxicity. 2021 , 9,	5
588	NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. 2021 , 10,	11
587	Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. 2021 , 6, 60	2
586	Nonalcoholic Fatty Liver Disease (NAFLD) Association with Pediatric Diabetes. 2021 , 181-189	
585	Nutraceuticals for Non-alcoholic Fatty Liver Disease. 2021 , 141-165	
584	Association of insulin resistance and non-alcoholic fatty liver disease. 2021 , 23, 412-423	
583	Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. 2021 , 12, 1	9
582	Therapeutic approaches for non-alcoholic steatohepatitis. 2021 , 12, 20420188211034300	1
581	Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. 2021 , 23, 980-990	18
580	Leber. 2021 , 443-582	
579	An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents. 2021 , 9, 60-70	2
578	Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan. 2021 , 15, 179-190	2
577	Nonalcoholic Fatty Liver Disease and Obesity. 2021 , 55, 27-35	0
576	Mitochondrial dysfunction and liver disease: role, relevance, and potential for therapeutic modulation. 2021 , 14, 17562848211031394	4
575	Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized, Open-Label Trial Study.	
574	Current treatment paradigms and emerging therapies for NAFLD/NASH. 2021 , 26, 206-237	21
573	Diabetes mellitus und Fettlebererkrankungen. 2021 , 16, 109-119	

572	Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. 2021 , 41, 731-742	4
571	Treatments for NAFLD: State of Art. 2021 , 22,	19
570	Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes. 2021 , 36, 134-145	1
569	Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus. 2021 ,	2
568	Therapeutic pipeline in nonalcoholic steatohepatitis. 2021 , 18, 373-392	46
567	Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial. 2021 , 23, 1129-1139	11
566	Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats. 2021 , 16, e0247303	5
565	Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study. 2021 , 51, 167-174	
564	GLP-1-Rezeptoragonisten bei NASH. 2021 , 8, 16-17	
563	Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis. 2020 , 11, 622589	4
562	Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. 2021 , 23, 1069-1083	28
561	INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". 2021 , 18, 5-99	20
560	Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. 2021 , 5, 938-946	4
559	An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy. 2021 , 14, 333-340	7
558	Efficacy and safety of drugs for nonalcoholic steatohepatitis. 2021 , 22, 72-82	7
557	Obesity as a multisystem disease: Trends in obesity rates and obesity-related complications. 2021 , 23 Suppl 1, 3-16	25
556	Semaglutid zur Behandlung der nichtalkoholischen Steatohepatitis. 2021 , 17, 220-222	
555	An update on pharmacotherapeutic strategies for obesity. 2021 , 22, 1305-1318	3

554	The Current and Potential Therapeutic Use of Metformin-The Good Old Drug. 2021 , 14,	15
553	NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. 2021 , 2021, 6613827	9
552	Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. 2021 , 5, 786-797	3
551	Regression of portal hypertension: underlying mechanisms and therapeutic strategies. 2021 , 15, 36-50	4
550	Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. 2021 , 14, 457-464	6
549	Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent. 2021 , 42, 183-190	5
548	Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions. 2021 , 43, 500-517	4
547	Role of mitochondria in liver metabolic health and diseases. 2021 , 94, 102336	13
546	Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?. 2021 , 15, 380-391	16
545	Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. 2021 , 9,	4
544	Treatment Candidacy for Pharmacologic Therapies for NASH. 2021 ,	6
543	Nonalcoholic Steatohepatitis: Case-Based Focused on Pediatric and Adult Guidelines. 2021 , 29-37	
542	The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. 2021 , 21, 15	11
541	Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes: A Network Meta-Analysis. 2021 , 12, 649018	1
540	Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. 2021 , 10,	2
539	Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. 2021 , 8, 615978	21
538	Non-alcoholic liver disease (NAFLD). 2021 , 211-216	
537	Diabetic fibrosis. 2021 , 1867, 166044	20

536	What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis. 2021 , 16, e0250385	1
535	Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. 2021 , 14, 837-852	1
534	Update on cardiovascular risk in nonalcoholic fatty liver disease. 2021 , 36, 478-486	0
533	Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. 2021 , 46, 101090	40
532	The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. 2021 , 12, 660179	13
531	Recent Perspectives for Combined Status of Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD). 2021 , 9-11	
530	Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. 2021 , 12, 609110	12
529	Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid Combination in Chronic Hepatitis Related to Metabolic Syndrome Components. 2021 , 77, 179-189	1
528	Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. 2021 , 27, 221-235	7
527	Therapeutic Approaches for Nonalcoholic Steatohepatitis (NASH). 1-71	
526	Eugenol modulates insulin sensitivity by upregulating insulin receptor substrate-2 in non-alcoholic fatty liver disease in rats. 2021 , 73, 846-854	2
525	Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. 2021 , 41, 1853-1866	5
524	Liver-targeting drugs and their effect on blood glucose and hepatic lipids. 2021 , 64, 1461-1479	8
523	Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. 2021 , 22,	9
522	Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. 2021 , 271, 119220	11
521	Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. 2021 , 9, 729	12
520	Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?. 2021 , 10,	1
519	Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-analysis. 2021 , 55, 586-593	0

518	Proglucagon-Derived Peptides as Therapeutics. 2021 , 12, 689678	7
517	Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article. 2021 , 13, e15141	5
516	Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands. 2021 ,	4
515	Blinding in Clinical Trials for Chronic Liver Diseases. 2021 , 41, 163-171	0
514	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. 2021 , 41, 235-247	1
513	Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?. 2021 , 22,	17
512	Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. 2021 , 44, 1433-1442	30
511	Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. 2021 , 12, 1735-1749	4
510	Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. 2021 , 27, 1864-1882	7
509	The Potential Application of Magnetic Nanoparticles for Liver Fibrosis Theranostics. 2021 , 9, 674786	9
508	The therapeutic potential of GLP-1 receptor biased agonism. 2021 ,	4
507	The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. 2021 , 18, 599-612	55
506	Early onset of acute pancreatitis in a patient on low-dose liraglutide. 2021 , 15, 753-755	2
505	Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. 2021 , 27, 2281-2298	0
504	Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. 2021 , 31, 14-26	
503	Role of the inflammasome, gasdermin D, and pyroptosis in non-alcoholic fatty liver disease. 2021 , 36, 2720-2727	4
502	Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 2021 , 41, 1713-1733	13
501	Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials. 2021 , 36, 647-660	4

500	Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. 2021 , 12, 645507	5
499	Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. 2021 , 17, 484-495	32
498	Non-alcoholic fatty liver disease. <i>Lancet, The</i> , 2021 , 397, 2212-2224	40 145
497	Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches. 2021 , 13,	6
496	Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. 2021 , 119, 154770	20
495	Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. 2021 , 44, 2089-2097	6
494	Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. 2021 , 11,	3
493	Current management of NAFLD/NASH. 2021 , 41 Suppl 1, 89-94	2
492	Noninvasive measure of treatment response in non-alcoholic steatohepatitis: Insights from EMMINENCE and meta-analysis. 2021 , 5, 740-749	1
491	Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients.. 2022 , 12, 435-439	1
490	Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. 2021 , 12, e00371	1
489	Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016. 2021 , 134, 1593-1601	8
488	Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. 2021 , 74, 1220-1233	12
487	Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. 2021 , 3, 100284	7
486	Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. 2021 ,	0
485	Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment. 2021 , 20, 416-425	4
484	Anti-diabetic drugs and NASH: from current options to promising perspectives. 2021 , 30, 813-825	2
483	2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. 2021 , 45, 461-481	31

482	Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review. 2021 , 41, 435-447	1
481	Brief Review of Portal Hypertension Related Complications.	
480	Preparing for the NASH Epidemic: A Call to Action. 2021 , 44, 2162-2172	5
479	Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. 2021 , 10,	5
478	Sarcopenic obesity as a determinant of cardiovascular disease risk in older people: a systematic review. 2021 , 133, 831-842	4
477	Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. 2021 , 6, 578-588	37
476	Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. 2021 , 10,	2
475	Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study. 2021 , 94, 111-120.e3	6
474	Semaglutide or Placebo for Nonalcoholic Steatohepatitis. 2021 , 385, e6	1
473	Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. 2021 ,	1
472	How glucagon-like peptide 1 receptor agonists work. 2021 , 10, R200-R212	4
471	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. 2021 , 27, 363-401	21
470	Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. 2021 , 5, 1833-1847	7
469	Chronic liver disease and oxidative stress - a narrative review. 2021 , 15, 1021-1035	2
468	Glucose-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes. 2021 ,	2
467	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. <i>Lancet, The</i> , 2021 , 398, 262-276	40 35
466	Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).. 2021 , 9, 939-946	0
465	Aspectos relevantes de la enfermedad por hígado graso no alcohólico. 2021 , 310-324	0

464	Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention. 2021 , 75, 1217-1227	4
463	Subclinical Liver Disease Is Associated with Subclinical Atherosclerosis in Psoriasis: Results from Two Observational Studies. 2021 ,	1
462	Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. 2021 , 13, e17321	0
461	GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. 2021 , 12, 721135	7
460	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. 2021 , 31, 3257-3270	4
459	Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. 2021 ,	7
458	Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. 2021 , 74, 2467-2477	2
457	The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. 2021 ,	10
456	Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease. 2021 , 27, 4999-5018	1
455	Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. 2021 , 54, 1013-1025	8
454	A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease. 2021 , 66, 3676-3688	2
453	The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis. 2021 , 74, 2290-2292	2
452	Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. 2021 , 3, 100305	13
451	Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity. 2021 , 37, 1867-1873	0
450	Ligustilide inhibited Angiotensin II induced A7r5 cell autophagy via Akt/mTOR signaling pathway. 2021 , 905, 174184	0
449	Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. 2021 , 1-18	8
448	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. 2021 , 13,	5
447	Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. 2021 , 121, 154796	1

446	Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide. 2021 , 10, 518-521	1
445	Preparing for the NASH epidemic: A call to action. 2021 , 29, 1401-1412	1
444	Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. 2021 , 43, 1476-1504	5
443	Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. 2021 , 54, 880-889	9
442	Metabolic hallmarks of liver regeneration. 2021 , 32, 731-745	3
441	Preparing for the NASH Epidemic: A Call to Action. 2021 , 161, 1030-1042.e8	7
440	Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design. 2021 , 48, 101281	0
439	GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH. 2021 , 12, 721198	0
438	Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. 2021 , 1-5	
437	Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. 2021 , 54, 1150-1161 ¹⁵	
436	Management of type 2 diabetes without insulin: An update for the PCP. 2021 , 101290	
435	Neue Entwicklungen in der Diagnostik und Therapie der metabolisch assoziierten, nicht-alkoholischen Fettlebererkrankung. 2021 , 15, 121-129	
434	Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. 2021 , 907, 174272	3
433	An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist.. 2022 , 12, 560-574	0
432	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. 2021 , 56, 951-963	14
431	Targeting Gut-Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. 2021 , 1, 147-179	0
430	Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. 2021 , 6, 1036-1046	0
429	Safety and Efficacy of Glucagon-like Peptide 1 Receptor Agonists in Patients With Cirrhosis. 2021 ,	0

428	Preparing for the NASH epidemic: A call to action. 2021 , 122, 154822	4
427	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. 2021 , 47, 101272	5
426	Verbesserung der nichtalkoholischen Steatohepatitis unter dem GLP-1-Rezeptor-Agonisten Semaglutid. 2021 , 2, 110-111	
425	Changing clinical management of NAFLD in Asia. 2021 ,	2
424	Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease: A Review of the Literature With Recommendations. 2021 , 55, 747-756	1
423	NAFLD in the Elderly. 2021 , 16, 1633-1649	4
422	Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. 2021 , 24, 100315	1
421	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. 2021 , 51, 1013-1025	7
420	Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. 2021 , 12, 1576-1586	1
419	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. 2021 , 161, 1657-1669	17
418	Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. 2021 , 9, 730176	13
417	Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. 2021 , 9,	7
416	Non-alcoholic fatty liver disease: A patient guideline. 2021 , 3, 100322	17
415	Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. 2021 , 31, 3474-3483	3
414	Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a case-control study. 2021 ,	
413	An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. 2021 , 60, 170-176	3
412	Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice. 2021 , 147, 176-183	3
411	Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. 2021 , 123, 154844	4

410	Impact of standard treatment on the quality of life of non-alcoholic fatty liver disease patients. 2021 , 16, 755-760	0
409	The pathophysiology of gut-liver connection. 2021 , 97-122	
408	Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). 2021 , 2310, 201-246	5
407	Sleeve Gastrectomy in Non-alcoholic Steatohepatitis (NASH) and Liver Cirrhosis. 2021 , 115-137	
406	Perception of Illness and Its Association with Treatment Willingness in Patients with Newly Diagnosed Nonalcoholic Fatty Liver Disease. 2021 , 66, 4197-4207	1
405	Shifting perspectives - interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals. 2021 , 13, 80-93	1
404	Novel glucose-lowering drugs for non-alcoholic fatty liver disease. 2021 , 12, 84-97	9
403	Pharmacological treatment of hyperglycemia in type 2 diabetes. 2021 , 131,	24
402	Management of non-alcoholic fatty liver disease. 2021 , 372, m4747	31
401	Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. 2021 , 1307, 417-440	3
400	NAFLD and Insulin Resistance: A Multisystemic Disease. 2020 , 49-71	1
399	Accounting for the Placebo Effect and Optimizing Outcomes in Clinical Trials of Nonalcoholic Steatohepatitis (NASH). 2020 , 19, 63-69	2
398	New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. 2020 , 72, 1-12	27
397	Work up of fatty liver by primary care physicians, review. 2020 , 50, 41-48	1
396	Serum lactate levels are associated with serum alanine aminotransferase and total bilirubin levels in patients with type 2 diabetes mellitus: A cross-sectional study. 2019 , 149, 1-8	2
395	Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics. 2020 , 11, 467	41
394	Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery. 2020 , 29, 107-110	1
393	A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis. 2021 , 33, 1420-1426	1

392	How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials. 2020 , 40, 506-522	20
391	Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. 2017 , 2,	30
390	Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. 2020 , 10,	10
389	Using a Reporter Mouse to Map Known and Novel Sites of GLP-1 Receptor Expression in Peripheral Tissues of Male Mice. 2021 , 162,	9
388	Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease. 2018 , 24, 7399-7404	7
387	Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology. 2019 , 36, 67-77	3
386	Relationship between non-alcoholic fatty liver disease and coronary heart disease. 2020 , 8, 4688-4699	9
385	Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. 2017 , 5, 67-75	15
384	Functional, Diagnostic and Therapeutic Aspects of Gastrointestinal Hormones. 2019 , 12, 233-244	6
383	New Concepts on Reversibility and Targeting of Liver Fibrosis; A Review Article. 2018 , 10, 133-148	22
382	Fighting liver fat. 2020 , 9, R173-R186	4
381	Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. 2019 , 241, 293-305	15
380	Position statement on the diagnosis and management of non-alcoholic fatty liver disease. 2019 , 40, 531-540	10
379	The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. 2020 , 112, 627-635	6
378	Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. 2018 , 31, 296-304	4
377	SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. 2020 , 59, 1931-1937	14
376	Risk of Kidney Dysfunction IN Nafld. 2020 , 26, 1045-1061	5
375	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. 2019 , 17, 515-537	12

374	Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. 2021 , 17, 94-111	3
373	Preliminary results of dulaglutide treatment in patients with non-alcoholic fatty liver disease (DEMOS study). 2020 , 4-10	1
372	NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. 2017 , 23, 103-108	28
371	Recent research trends and updates on nonalcoholic fatty liver disease. 2019 , 25, 1-11	47
370	Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. 2020 , 26, 430-443	12
369	Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. 2020 , 11,	22
368	Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. 2018 , 24, 179-194	66
367	Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. 2020 , 26, 2740-2757	9
366	Medications in type-2 diabetics and their association with liver fibrosis. 2020 , 26, 3249-3259	3
365	Efficacy and safety of anti-hepatic fibrosis drugs. 2020 , 26, 6304-6321	12
364	Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review). 2020 , 20, 2387-2391	1
363	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. 2020 , 44, 382-401	16
362	Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. 2020 , 44, 640-657	7
361	Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. 2020 , 44, 802-818	17
360	Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome. 2016 , 7, 441-448	15
359	Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease. 2019 , 11, 562-573	7
358	Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. 2020 , 12, 493-505	11
357	Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. 2020 , 12, 533-557	3

356	Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver. 2020 , 9,	3
355	Association of Non-alcoholic Fatty Liver Disease with Conduction Defects on Electrocardiogram. 2017 , 9, e1107	10
354	Non-Alcoholic Fatty Liver Disease Association with Cardiac Arrhythmias. 2017 , 9, e1165	8
353	Non-alcoholic fatty liver disease. 2020 , 20, 509-512	3
352	Nonalcoholic Fatty Liver Disease. 2022 , 295-323	
351	Analysis of Mechanistic Pathways in the Treatment of Non-Alcoholic Steatohepatitis. Evidence from a Bayesian Network Meta-Analysis.	0
350	Untargeted serum metabolites profiling in high-fat diet mice supplemented with enhanced palm tocotrienol-rich fraction using UHPLC-MS. 2021 , 11, 21001	1
349	GLP-1 physiology informs the pharmacotherapy of obesity. 2021 , 57, 101351	9
348	Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. 2021 , 8, 761538	1
347	Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. 2021 , 2021, 3715026	0
346	Dapagliflozin, as Add-on Therapy in Type 2 Diabetes Patients, Is Associated With a Reduction in Albuminuria and Serum Transaminase Levels. 2021 , 2,	
345	Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis. 2021 ,	1
344	Novel therapeutic targets for cholestatic and fatty liver disease. 2022 , 71, 194-209	7
343	Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. 2021 ,	4
342	Synthetic glabridin derivatives mitigate steatohepatitis in a diet-induced biopsy-confirmed non-alcoholic steatosis hepatitis mouse model through paraoxonase-2.	0
341	Therapy of nonalcoholic steatohepatitis (NASH). 2016 , 18, 233-235	
340	Nonalcoholic Fatty Liver Disease. 2017 ,	
339	Nonalcoholic Fatty Liver Disease. 2017 , 65-82	

- 338 Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes. **2018**, 47-69
- 337 Obesity and NAFLD. **2018**, 1-16
- 336 Leber. **2018**, 321-451
- 335 Management of Nonalcoholic Fatty Liver Disease and Metabolic Syndrome. **2018**, 406-411.e2
- 334 Diabetes and NAFLD. **2018**, 495-521
- 333 Pathogenetic substantiation of approaches to the treatment of non-alcoholic fatty liver disease.. **2018**, 95, 1077-1085
- 332 The relationship between serum dipeptidyl peptidase-4 enzyme and nonalcoholic fatty liver disease in diabetic and nondiabetic patients. **2018**, 30, 49-53
- 331 Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms. **2018**, 64, 735-741
- 330 Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?. **2018**, 24, 299-301
- 329 Liver Cirrhosis with Steatohepatitis: Nonalcoholic Steatohepatitis and Alcoholic Steatohepatitis. **2019**, 1-21
- 328 Diabète et complications hépatiques. **2019**, 345-351
- 327 Diabetes and NAFLD. **2019**, 1-27
- 326 LUXendins reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics.
- 325 Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of non-alcoholic steatohepatitis.
- 324 What influences treatment response in animal models of non-alcoholic fatty liver disease? A meta-analysis with meta-regression.
- 323 Diabetes and NAFLD. **2020**, 495-521
- 322 Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. **2020**, 33, 603-614
- 321 The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future. **2019**, 22, 461-466

- 320 GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis. **2020**, 1, 108-123 2
- 319 Severe Visceral Obesity, Fatty Liver and Diabetes after Orchiectomy for Prostate Cancer. **2020**, 59, 2281-2285 0
- 318 Detection of NAFLD/NASH in the General Population and in Primary Care Clinics. **2020**, 11-27
- 317 Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. **2021**, 9, 40-50 4
- 316 Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial. **2021**, 5, 193-198 2
- 315 What may GLP1 receptor agonists contribute to the treatment of patients with non-alcoholic fatty liver disease?. **2020**, 112, 587-589
- 314 Pharmacological Options for NASH. **2020**, 309-327
- 313 Nonalcoholic Fatty Liver Disease. **2020**, 325-334
- 312 VII. The Evidence of Pharmacologic Treatment for NASH. **2020**, 109, 56-63
- 311 Oral GLP1 Analog: Where Does the Tide Go?. **2020**, 13, 1179551420984130 2
- 310 Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. **2022**, 126, 154925 23
- 309 Advances in the treatment of nonalcoholic steatohepatitis. **2020**, 9, 1-12
- 308 New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis. **2021**, 9, 51-59 1
- 307 Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials. **2016**, 12, 756-763 10
- 306 Pharmacologic Management of Nonalcoholic Steatohepatitis. **2018**, 14, 582-589 3
- 305 Population Management of Nonalcoholic Fatty Liver Disease. **2019**, 36, 72-82 2
- 304 Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?. **2019**, 36, 64-71 17
- 303 Fatty liver disease in persons with HIV infection. **2019**, 27, 75-82 11

302	[Effect of glucagon-like peptide 1 receptor agonists on body fat redistribution and muscle mass in overweight and obese type 2 diabetic patients]. 2019 , 39, 450-455	
301	Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai'i. 2020 , 79, 180-186	
300	Drugs and Mechanisms Related to the Treatment of Nonalcoholic Fatty Liver Disease. 2021 , 11, 5237-5244	
299	Polycystic ovary syndrome and nonalcoholic fatty liver disease. 2022 , 187-216	0
298	Liraglutide with Lifestyle Intervention in Adolescents with Overweight/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus. 2021 , 2, e141	0
297	A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). 2021 , 11, 22063	8
296	Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. 2021 , 6, 918-932	6
295	GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. 2021 , 2021, 8936865	7
294	Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity.. 2021 , 13, 1584-1610	2
293	Diabetestherapie bei fortgeschrittenen Lebererkrankungen und Leberzirrhose. 2022 , 18, 26	
292	The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer. 2021 , 13,	1
291	Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. 2021 , 326, 2031-2042	19
290	Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks. 2021 , 14, 457-465	0
289	A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome. 2021 ,	1
288	Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. 2021 ,	1
287	"Glycemic Control, the Unconsidered Outcome in the Treatment of Nonalcoholic Fatty Liver Disease". 2021 , 100648	0
286	Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. 2021 , 42, 101213	5
285	Nichtalkoholische Fettlebererkrankung (NAFLD). 2016 , 1-7	

- 284 Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice.. **2021**, 17, 112-120
- 283 Glucose-lowering agents and reduced risk of incident non-alcoholic fatty liver disease: new insights.. **2022**, 11, 156-160
- 282 Pharmacology of NASH. **2021**,
- 281 Elevated liver enzymes and comorbidities in type 2 diabetes: Multicenter analysis of 51,645 patients of the DPV database. **2021**,
- 280 GLP-1a: Going beyond Traditional Use.. **2022**, 23, 7
- 279 The metabolic triad of NAFLD, visceral adiposity and type 2 diabetes: implications for treatment.. **2022**, 2
- 278 Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week.. **2022**, 79, 180-191 3
- 277 Diabetes bei Leberinsuffizienz: Zielgerichtete Auswahl und Dosierung der Antidiabetika.
- 276 Diagnosis and management of fatty liver. **2020**, 50, 256-261
- 275 Glycaemic Control in Diabetes. **2021**, 47
- 274 NAFLD and NASH: The Metabolically Diseased Liver. **2021**, 1 0
- 273 Glucagon-Like Peptide-1 Receptor Agonists-Use in Clinical Practice.. **2021**, 28, 328-336 0
- 272 An algorithm for the management of non-alcoholic fatty liver disease in primary care. **2021**, 12, 114-122
- 271 Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease.. **2022**, 23, 1
- 270 Future pharmacotherapy for non-alcoholic steatohepatitis.. **2022**, 34, 225-227
- 269 Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates.. **2022**, 10, 2
- 268 The Malaysian Society of Gastroenterology and Hepatology Consensus Statement on Metabolic Dysfunction-Associated Fatty Liver Disease.. **2022**, 3
- 267 Adherence to lifestyle modification in patients with nonalcoholic fatty liver disease. **2022**, 20, 112-122

266	Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis.. 2022 , 59, 519	1
265	PSD3 downregulation confers protection against fatty liver disease.. 2022 , 4, 60-75	1
264	Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease.. 2022 , 12, 283	0
263	A Unique Immune-Related Gene Signature Represents Advanced Liver Fibrosis and Reveals Potential Therapeutic Targets.. 2022 , 10,	0
262	Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.. 2022 ,	6
261	Liraglutide + PYY Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements.. 2022 , 11,	0
260	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. 2021 ,	1
259	Placebo Effect on Progression and Regression in Non-Alcoholic Steatohepatitis. Evidence from a Meta-Analysis.. 2022 ,	4
258	Non-alcoholic fatty liver disease and type 2 diabetes - An Update.. 2022 ,	2
257	Metabolic dysfunction-associated fatty liver disease - How relevant is this to primary care physicians and diabetologists?. 2022 ,	0
256	Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis. 2022 , 31, 16-24	
255	Combination Therapy with Pioglitazone/Exenatide Metformin Reduces the Prevalence of Hepatic Fibrosis and Steatosis: The Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) Trial.. 2022 ,	0
254	Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.. 2022 ,	3
253	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. 2021 ,	1
252	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). 2022 , 5, 61-90	0
251	Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.. 2022 ,	1
250	Direct comparison of the effects of liraglutide and dulaglutide on the dynamics of scales and markers of hepatic fibrosis. 2021 , 82-90	
249	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022.. 2022 , 45, S46-S59	8

248	Nonalcoholic Fatty Liver Disease. 2022 , 443-450	
247	Adipose tissue. 2022 , 209-228	
246	Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development. 2022 , 7, 39-49	
245	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. 2022 , 94, 216-253	5
244	Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.. 2022 , 9, 793203	1
243	Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus.. 2022 , 37, 26-37	1
242	Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.. 2022 ,	1
241	Therapeutic developments in metabolic dysfunction-associated fatty liver disease.. 2022 ,	1
240	Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.. 2022 , 17, e0261310	0
239	State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis.. 2022 , 37, 38-52	0
238	Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review.. 2022 ,	1
237	What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review.. 2022 ,	1
236	Nonalcoholic Fatty Liver Disease and Endocrine Axes-A Scoping Review.. 2022 , 12,	3
235	Review article: current and emerging therapies for the management of cirrhosis and its complications.. 2022 ,	2
234	Implementation of Cardiometabolic Centers and Training Programs.. 2022 , 1	
233	Metabolic Syndrome and Metabolic Dysfunction-Associated Fatty Liver Disease. 2022 , 159-177	
232	Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study.. 2022 , 1	0
231	Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis.. 2022 ,	0

230	Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.. 2022 , 21, 36	1
229	Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.. 2022 ,	1
228	The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment.. 2022 , 13, 780496	2
227	Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis.. 2022 , 16, 102446	0
226	Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.. 2022 , 57, 357	1
225	The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease.. 2022 , 26, 213-227	0
224	Expanded LUXendin Color Palette for GLP1R Detection and Visualization In Vitro and In Vivo.. 2022 , 2, 1007-1017	1
223	A global view of the interplay between non-alcoholic fatty liver disease and diabetes.. 2022 ,	18
222	GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.. 2021 ,	0
221	Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.. 2021 , 20, 237	2
220	Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem.. 2021 , 9,	3
219	Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).. 2021 , 13, e20776	1
218	PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.. 2021 , 1-11	0
217	Reagents and models for detecting endogenous GLP1R and GIPR.. 2021 , 74, 103739	2
216	and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation.. 2021 , 13, 1991-2004	
215	Pharmacotherapy of obesity in complex diseases. 2021 , e12497	1
214	Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.. 2021 , 9,	1
213	Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis.. 2021	2

212	Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.. 2021 , 12, 769069	2
211	Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota.. 2021 , 14,	4
210	Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management.. 2021 ,	0
209	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.. 2021 , 10,	2
208	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. 2021 , 1	1
207	Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.. 2021 , 12, 768850	0
206	The impact of health status, diet and lifestyle on non-alcoholic fatty liver disease: Narrative review.. 2022 , e12525	0
205	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.. 2022 , 101161ATV00000000000000153	9
204	Semaglutide: a game changer for metabolic diseases?. 173-180	0
203	Potential Therapeutic Targets and Promising Agents for Combating NAFLD.. 2022 , 10,	0
202	Data_Sheet_1.PDF. 2020 ,	
201	General Overview About the Current Management of Nonalcoholic Fatty Liver Disease.. 2022 , 1	0
200	Nonalcoholic Fatty Liver Disease in Children.. 2021 , 17, 579-587	
199	Liver Steatosis: A Marker of Metabolic Risk in Children.. 2022 , 23,	1
198	The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study. 2022 , 12,	
197	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).. 2022 , 28, 528-562	16
196	Reply to the Letter to the editor "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".. 2022 ,	
195	Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease.. 2022 ,	2

194	Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.. 2022 ,	2
193	SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease.. 2022 ,	1
192	CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE.. 2021 , 60, 36-52	
191	Agonisti del recettore del GLP1 e infiammazione: non solo compenso glicemico.	
190	Breakthroughs in therapies for NASH and remaining challenges.. 2022 , 76, 1263-1278	1
189	Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.	0
188	What's new in non-alcoholic fatty liver disease?. flgastro-2022-102122	1
187	Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults.	0
186	Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. 2022 , 11, 1060	
185	A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis.	0
184	A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. 2022 , Publish Ahead of Print,	1
183	Non-Alcoholic Steatohepatitis Drug Development Pipeline: An Update.	0
182	Identification of Key Biomarkers and Immune Infiltration in Liver Tissue after Bariatric Surgery. 2022 , 2022, 1-17	0
181	Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease.	0
180	The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer.	0
179	New Drugs for Hepatic Fibrosis. 13,	1
178	The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. 2022 , 100525	0
177	Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study.	0

- 176 The Benefit of Bariatric Surgery on Histological Features of Metabolic Associated Fatty Liver Disease Assessed Through Noninvasive Methods. 0
- 175 Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis. **2022**, 16, 102539 0
- 174 Current therapies and new developments in NASH. *gutjnl-2021-326874* 6
- 173 Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?. **2022**, 29, 4478-4510 0
- 172 Evaluated Glomerular Filtration Rate Is Associated With Non-alcoholic Fatty Liver Disease: A 5-Year Longitudinal Cohort Study in Chinese Non-obese People. 9, 0
- 171 When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. **2022**, 11, 3286 0
- 170 Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases. **2022**, 152, 113236 0
- 169 Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents. **2022**, 23, 83-88
- 168 GLP-1 Receptor Agonists. **2022**, 130-160
- 167 Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. **2022**, 37, 415-429 0
- 166 Nomogram for Quantitatively Estimating the Risk of Fibrosis Progression in Type 2 Diabetic Patients With Nonalcoholic Fatty Liver Disease: A Pilot Study. 13,
- 165 Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis. **2022**, 22,
- 164 Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. 1
- 163 Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. **2022**, 0
- 162 Current treatment of non-alcoholic fatty liver disease. 0
- 161 AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. **2022**, 6
- 160 Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. 13, 0
- 159 Postprandial glucose is correlated with an increasing risk of liver fibrosis in Chinese patients with nonalcoholic fatty liver disease. **2022**, 101377 0

158	Banting Memorial lecture 2022: Type 2 diabetes and nonalcoholic fatty liver disease: partners in crime	0
157	Combination Therapies for Nonalcoholic Fatty Liver Disease. 2022 , 12, 1166	0
156	Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. 2022 , 10, 6759-6768	0
155	An overview of ferroptosis in non-alcoholic fatty liver disease. 2022 , 153, 113374	0
154	Recent advances in lean NAFLD. 2022 , 153, 113331	2
153	Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients : what do we know so far ?. 2022 , 85, 346-357	0
152	IRX3 plays an important role in the pathogenesis of metabolic-associated fatty liver disease by regulating hepatic lipid metabolism. 13,	0
151	Endoplasmic reticulum stress in innate immune cells -a significant contribution to non-alcoholic fatty liver disease. 13,	1
150	A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes. 9,	0
149	Nonalcoholic Steatohepatitis in Children. 2022 , 26, 439-460	
148	Development and prognosis of hepatocellular carcinoma in patients with diabetes.	0
147	Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial.	0
146	Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease.	1
145	Impact of duodenal-jejunal bypass liner (DJBL) on NAFLD in patients with obesity and type 2 diabetes mellitus. 2022 , 111806	
144	European guideline on obesity care in patients with gastrointestinal and liver diseases Joint ESPEN/UEG guideline. 2022 ,	4
143	Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease.	1
142	Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. 2022 , 14, 4051	2
141	Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine. 13,	

140	Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes. 13,	1
139	Review article Management of NAFLD in primary care settings.	1
138	Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). 2022, 7,	4
137	Modifying a Hydroxyl Patch in Glucagon-like Peptide 1 Produces Biased Agonists with Unique Signaling Profiles.	
136	Disease state transition probabilities across the spectrum of NAFLD: A systematic review and meta-analysis of paired biopsy or imaging studies. 2022,	0
135	Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.	0
134	Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents. 2022, 100751	0
133	Liraglutide Exerts Protective Effects by Downregulation of PPAR α ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis. 2022, 44, 3465-3480	1
132	The effects of the voglibose on non-alcoholic fatty liver disease in mice model. 2022, 12,	
131	Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective. 2022, 184, 106426	1
130	Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie. 2022, 211-225	0
129	Nonalcoholic steatohepatitis-induced hepatocellular carcinoma. 2022, 7, 1	0
128	Diagnostik: Blutbasierte Marker. 2022, 149-155	0
127	Spezifische Therapie [neue Medikamente]. 2022, 227-255	0
126	Medikamentenstoffwechsel. 2022, 311-322	0
125	Antifibrotic effect and long-term outcome of SGLT 2 inhibitors in patients with NAFLD complicated by diabetes mellitus.	0
124	Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus—from Prevalence to Diagnostic Approach and Treatment Strategies. 2022, 11, 5144	1
123	Gastrointestinal and Liver Complications in Patients with Diabetes Mellitus—a Review of the Literature. 2022, 11, 5223	0

122	Impact of refitted race-free eGFR formula on obesity pharmacotherapy options.	0
121	Advances in metformin for the treatment of non-alcoholic fatty liver disease in children. 1-15	0
120	Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) [April 2022] AWMF Registration No.: 021025. 2022 , 60, e733-e801	0
119	Therapies for non-alcoholic fatty liver disease: A 2022 update. 14, 1718-1729	0
118	Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers. 2022 , 97, 1700-1716	2
117	Placebo Adverse Events in Non-Alcoholic Steatohepatitis Clinical Trials. A Pooled Analysis of 2,944 Participants. 2022 , Publish Ahead of Print,	0
116	Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) [April 2022] AWMF-Registernummer: 021025. 2022 , 60, 1346-1421	0
115	How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma. 2022 , 14, 4651	0
114	Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. 2022 , 28, 5129-5140	0
113	Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. 2022 , 100456	0
112	Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study. 2022 , 18, 140-145	1
111	A Review of Defatting Strategies for Non-Alcoholic Fatty Liver Disease. 2022 , 23, 11805	1
110	A Gedunin-Type Limonoid, 7-Deacetoxy-7-oxogedunin, from Andiroba (<i>Carapa guianensis</i> Aublet) Reduced Intracellular Triglyceride Content and Enhanced Autophagy in HepG2 Cells. 2022 , 23, 13141	0
109	Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD). 2022 , 2, 264-282	0
108	NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?.	0
107	The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence?. 2022 , 4, 132-141	0
106	Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NAFLD Mice via miR-5120/ABHD6. Volume 16, 3557-3572	0
105	β-Sulfono-βAA peptide hybrids agonist of GLP-1R with prolonged action both in vitro and in vivo. 2022 ,	0

104	Approach to the Patient with Nonalcoholic Fatty Liver Disease.	0
103	The Molecular Mechanisms of Liver Fibrosis and Its Potential Therapy in Application. 2022 , 23, 12572	0
102	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis.	0
101	Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis. 13,	0
100	Type 2 diabetes. 2022 ,	5
99	Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease. 13,	2
98	Pharmacotherapy of type 2 diabetes: An update and future directions. 2022 , 137, 155332	3
97	The treatment of diabetes in advanced liver disease: Change of a paradigm. 2023 , 28, 100772	0
96	Non-alcoholic Fatty Liver Disease. 2022 , 127-149	0
95	Management of non-alcoholic fatty liver disease patients with sleep apnea syndrome. 28, 6099-6108	0
94	O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease. 2022 , 11, 3637	1
93	Therapeutic Approach to NAFLD-NASH.	0
92	Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. 2022 , 2022, 1-9	0
91	NAFLD as the metabolic hallmark of obesity.	0
90	Targeting MRG15 for the treatment of nonalcoholic steatohepatitis. 2022 , 100217	0
89	Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: a network meta-analysis. 2022 , 102053	0
88	Emerging pharmacological treatment options for MAFLD. 2022 , 13, 204201882211424	0
87	Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver DiseaseCurrent Evidence. 2022 , 27, 1074249-10811469	1

86	Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. 2023 , 35, 1-14	1
85	Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis. 2022 , 18, 148	0
84	Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. 2022 , 32, 104-140	1
83	Bariatric endoscopic-surgical therapies for NAFLD. Should they be considered viable options among current treatments?. 13,	0
82	Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. 2022 , 9, 419	1
81	Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future.	0
80	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes. 2023 , 46, S49-S67	0
79	Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1.	1
78	Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration. 2022 , 14, 5340	0
77	Comparison between obese and non-obese NAFLD.	0
76	The Efficacy of Using Liraglutide for Improving Non-Acoholic Fatty Liver Disease Condition in Pediatric-Adolescent Population with Obesity: Real World Evidence. 2022 , 12, 361-366	0
75	Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity. 2023 , 31, 74-82	0
74	Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent. 2022 ,	1
73	Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity. 2022 ,	0
72	Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different. 2022 , 23, 16226	1
71	Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. 2022 , 21,	3
70	Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. 2022 , 7,	4
69	Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. 2023 , 15, 23	2

- 68 Die Rolle inkretinbasierter Therapien bei NAFLD/NASH. **2022**, 22, 24-27 ○
- 67 Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Non-alcoholic Fatty Liver Disease (NAFLD). **2022**, ○ 1
- 66 Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. **2023**, 24, 158 ○
- 65 Antidiabetic agents: Do they hit the right targets?. **2022**, 2, 225-243 ○
- 64 Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). 13, ○
- 63 Liver Fibroblast Growth Factor 21 (FGF21) is Required for the Full Anorectic Effect of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Male Mice Fed High Carbohydrate Diets. ○
- 62 GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. **2023**, 24, 1703 ○
- 61 Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies. 29, 75-95 ○
- 60 Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. 29, 286-309 ○
- 59 Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. **2023**, 8, 179-191 1
- 58 NAFLD and type 2 diabetes: A practical guide for the joint management. **2022**, ○
- 57 Compartmentalizing risk with sarcopenic obesity. Publish Ahead of Print, ○
- 56 Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial. **2023**, Publish Ahead of Print, ○
- 55 Medical therapy. **2023**, 353-361 ○
- 54 Nonalcoholic fatty liver disease. **2023**, 83-97 ○
- 53 Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease. Volume 19, 77-96 ○
- 52 Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. **2023**, 24, 2844 ○
- 51 AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Publish Ahead of Print, 5

- 50 An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. **2023**, ○
- 49 Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. **2023**, 59, 152165 ○
- 48 Cardiometabolic risk factors efficacy of semaglutide in the STEP program. **2022**, 134, 18-27 ○
- 47 Metabolic-associated fatty liver disease: pharmacological management. **2023**, 319-341 ○
- 46 Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: pathophysiology and implications for cardiovascular disease. **2023**, 137-173 ○
- 45 Current and emerging medications for the management of obesity in adults. **2023**, 218, 276-283 ○
- 44 Practical Guideline on Obesity care in patients with gastrointestinal and liver diseases [Joint ESPEN /UEG guideline. **2023**, ○
- 43 Economic Burden and Patient-Reported Outcomes of Nonalcoholic Fatty Liver Disease. **2023**, 27, 483-513 ○
- 42 Metabolic Syndrome and Its Association with Nonalcoholic Steatohepatitis. **2023**, 27, 187-210 ○
- 41 Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease. **2023**, 27, 429-449 ○
- 40 Current Treatment Options, Including Diet, Exercise, and Medications. **2023**, 27, 397-412 ○
- 39 Changings and Challenges in Liver Transplantation for Nonalcoholic Fatty Liver Disease/Steatohepatitis. **2023**, 27, 225-237 ○
- 38 Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets. **2023**, 72, 101718 ○
- 37 Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials. **2023**, 17, 273-282 ○
- 36 Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond. **2023**, 38, 25-33 ○
- 35 Obesity Pharmacotherapy: a Review of Current Practices and Future Directions. **2023**, 21, 27-47 ○
- 34 Emerging Therapeutic Targets for Portal Hypertension. **2023**, 22, 51-66 ○
- 33 Nonalcoholic fatty liver disease from a primary care perspective. ○

- 32 Efecto de semaglutida sobre los biomarcadores de la enfermedad del hígado graso en pacientes con diabetes y obesidad. **2023**, 223, 134-143 ○
- 31 Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: a retrospective study. **2023**, ○
- 30 Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association. Publish Ahead of Print, ○
- 29 Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease. **2023**, ○
- 28 Challenges and opportunities in NASH drug development. **2023**, 29, 562-573 ○
- 27 The Multifaceted Roles of Macrophages in NAFLD Pathogenesis. **2023**, 15, 1311-1324 ○
- 26 Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. 14, ○
- 25 Exploiting the biological effect exerted by lipid nanocapsules in non-alcoholic fatty liver disease. **2023**, 356, 542-553 ○
- 24 Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. **2023**, ○
- 23 Semaglutide in NASH-related cirrhosis: too late to the party?. **2023**, ○
- 22 Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. 14, ○
- 21 The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus. **2023**, 13, 839 ○
- 20 Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes. **2023**, 13, 558 1
- 19 Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. **2023**, 58, 101882 ○
- 18 Risk Scores for Prediction of Major Cardiovascular Events in Non-Alcoholic Fatty Liver Disease: A No Man's Land?. **2023**, 13, 857 ○
- 17 GLP1R agonists in NAFLD: a promising therapy on the horizon. ○
- 16 Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. ○
- 15 The expanding incretin universe: from basic biology to clinical translation. ○

- 14 GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease. **2023**, 77, 1-8
- 13 Voies thérapeutiques dans l'hépatopathie stéatosique métabolique. **2023**,
- 12 Hígado graso (parte 2): enfoque clínico y tratamiento. **2023**, 38, 46-58
- 11 A proposal from the Liver Forum for the management of comorbidities in nonalcoholic steatohepatitis therapeutic trials. **2023**,
- 10 Current, emerging, and potential therapies for non-alcoholic steatohepatitis. 14,
- 9 Insulin resistance and cardiovascular disease. **2023**, 51, 030006052311645
- 8 Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications. **2023**, 365-396
- 7 Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes. **2023**, 13, 517
- 6 Fatty Liver Disease. **2024**, 330-401
- 5 What is Obesity?. **2023**,
- 4 The complex link between non-alcoholic fatty liver disease and type 2 diabetes mellitus. **2023**, 1, 32
- 3 The role of ChREBP in carbohydrate sensing and NAFLD development.
- 2 Longitudinal changes in serum adipon levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease.
- 1 Endocrinology for the hepatologist. Publish Ahead of Print,